Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9395555 | Transplantation Proceedings | 2005 | 4 Pages |
Abstract
Five of 11 (45.5%) rats that were treated with 50 mg/kg β-SQAG9 liposome showed graft survival and another showed moderate rejection in graft. The CD62L+ T-cell subset population in ALNs of β-SQAG9 liposome-treated rats decreased in a dose-dependent manner. No significant difference in the T-cell population was observed between the β-SQAG9 and control groups. These data suggest that β-SQAG9 could bind to the CD62L+ T-cell subset in vivo as well as in vitro and affect T-cell migration, which might lead to T-cell tolerance in vivo.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
M. Takenouchi, H. Sahara, Y. Yamamoto, Y. Matsumoto, A. Imai, T. Fujita, Y. Tamura, N. Takahashi, S. Gasa, K. Matsumoto, K. Ohta, F. Sugawara, K. Sakaguchi, K. Jimbow, N. Sato,